Jiny Kim - Dec 13, 2023 Form 4 Insider Report for Cytosorbents Corp (CTSO)

Role: Director
Signature: /s/ Kathleen P. Bloch attorney-in-fact for Jiny Kim
Stock symbol: CTSO
Transactions as of: Dec 13, 2023
Transactions value $: $10,000
Form type: 4
Date filed: 12/15/2023, 04:31 PM
Previous filing: Jul 11, 2023
Next filing: Apr 4, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CTSO	Common Stock	Purchase	$10K	+7.52K	+10.7%	$1.33	77.8K	Dec 13, 2023	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CTSO	Common Stock Warrant (Right to Buy)	Purchase		+2.63K			2.63K	Dec 13, 2023	Common Stock	2.63K	$2.00	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These securities were purchased by the reporting person in the registered direct offering of CytoSorbents Corporation (the "Company"), which closed on December 13, 2023. In the offering, each share of common stock, par value $0.001 per share (the "Common Stock") of the Company was purchased together with an accompanying warrant to purchase up to 0.35 shares of Common Stock, at a combined offering price of $1.33 per share of Common Stock and accompanying warrant.
F2	Includes (a) 69,300 restricted stock units ("RSUs") granted on April 1, 2022 that will be settled into shares of Common Stock upon vesting upon a "Change In Control" of the Company as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan") and (b) 8,519 shares of Common Stock owned by the reporting person.

Content

These securities were purchased by the reporting person in the registered direct offering of CytoSorbents Corporation (the "Company"), which closed on December 13, 2023. In the offering, each share of common stock, par value $0.001 per share (the "Common Stock") of the Company was purchased together with an accompanying warrant to purchase up to 0.35 shares of Common Stock, at a combined offering price of $1.33 per share of Common Stock and accompanying warrant.

Includes (a) 69,300 restricted stock units ("RSUs") granted on April 1, 2022 that will be settled into shares of Common Stock upon vesting upon a "Change In Control" of the Company as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan") and (b) 8,519 shares of Common Stock owned by the reporting person.